Emerging Markets Earnings Roundup: Merck, Bristol Myers Squibb, Novo Nordisk (Part 12)
This article was originally published in PharmAsia News
Executive Summary
Merck played cat and mouse on the first quarter earnings call, but its subsequent deal with Bayer put the remarks in context. Bristol Myers Squibb has to wait on China for approval there of its diabetes deal with AstraZeneca and Novo Nordisk gets hit by emerging market currencies.